[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant

901.O2.6 901. Health Services and Outcomes Research: Health Services Research in Malignant Hematological Disorders

Program: Oral and Poster Abstracts
Type: Oral
Monday, December 12, 2011: 10:30 AM-12:00 PM
Elizabeth Ballroom FG (Manchester Grand Hyatt San Diego)
Smita Bhatia, MD, MPH, City of Hope and K. Scott Baker, MD, MS, Fred Hutchinson Cancer Research Ctr.

No relevant conflicts of interest to declare.
10:30 AM
Medicare Fee-for-Service Enrollees with Acute Myelogenous Leukemia: An Analysis of Treatment Patterns and Patient Survival

Juliana Leah Meyers, MA1*, Yanni F Yu2* and Keith L Davis1*

1Health Economics, RTI Health Solutions, Research Triangle Park, NC
2Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT

10:45 AM
The Limited Screening Value of Insulin-Like Growth Factor-I in 610 Very Long Term Adult Survivors of Leukemia and Other Types of Childhood CancerClinically Relevant Abstract

Karin Blijdorp1*, Marry M. van den Heuvel, MD, PhD2*, Rob Pieters, MD, PhD3, Annemieke Boot4*, Aartjan van der Lely5* and Sebastian J.C.M.M. Neggers, MD, PhD6*

1Pediatric Oncology, Erasmus University, Rotterdam, Netherlands
2Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, Netherlands
3Dept. of Pediatric Hematology/Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, Netherlands
4Pediatric endocrinology, Academic Medical Centre Groningen (UMCG)
5Internal Medicine, Erasmus MC–University Medical Center Rotterdam
6Department of Medicine, section Endocrinology, Erasmus University Medical Center , Rotterdam, Netherlands

11:00 AM
Hiatus in Infant Acute Leukemia Incidence rates in Belarus: Adaptation-to-Low-Dose-Radiation Phenomenon?

Vadim Ivanov, MD, PhD1, Tatiana Terehovich, MD, PhD2* and Eugene Ivanov, MD, PhD3*

1Hematology, Institut Paoli-Calmettes, Marseille, France
2Republican Scientific and Practical Centre of Medical Technologies, Minsk
3Department of Radiochemistry, Belarussian State University, Minsk, Belarus

11:15 AM
Success in Meeting the Primary Endpoint in Phase III Trials: A Comparison of Industry and Cooperative Group Trials

Benjamin Djulbegovic, MD, PhD1, Ambuj Kumar, MD, MPH2, Branko Miladinovic, PhD3*, Asmita Mhaskar, MPH4*, Tea Reljic, BS3*, Sanja Galeb, BS5*, Rahul Mhaskar, MPH, PhD4*, Hozo Iztok, PhD6*, Dongsheng Tu7*, Heather Stanton7*, Christopher M Booth7* and Ralph M. Meyer, MD7

1Center for evidence based medicine and health outcomes research, University of South Florida , Tampa, FL
2University of South Florida, College of Medicine, Center for Evidence Based Medicine, Tampa
3Center for Evidence-based Medicine , University of South Florida , Tampa, FL
4Center for Evidence-Based Medicine, University of South Florida, Tampa, FL
5Moffitt Cancer Center, Tampa, FL
6Indiana University Northwest, gary, IN
7NCIC CTG, Kingston, Canada

11:30 AM
Level of Scientific Evidence Underlying Recommendations Arising From the National Comprehensive Cancer Network Clinical Practice Guidelines for Hematologic Malignancies

Benny Kusuma, MD1* and Ronald S. Go, MD2

1Internal Medicine, Gundersen Lutheran Health System, La Crosse, WI
2Center for Cancer and Blood Disorders, Gundersen Lutheran Health System, La Crosse, WI

11:45 AM
Increased Cytogenetic Testing and Prognostic Assessment Do Not Translate Into Higher Active Treatment of Elderly MDS Patients in GermanyClinically Relevant Abstract

Norbert Gattermann, MD1, Andrea Kuendgen, MD2*, Lenka Kellermann, BS, MBA3*, Matti Zeffel, BS4*, Bernadette Paessens, PhD5* and Ulrich Germing, MD6*

1Heinrich-Heine-Universitat, Düsseldorf, Germany
2Heinrich-Heine University of Düsseldorf, Duesseldorf, Germany
3OncologyInformationService, Freiburg, Germany
4Market Research, Celgene GmbH, Munich, Germany
5Medical Communications, Celgene GmbH, D-81829 Munich, Germany
6Hematology, University Hospital Düsseldorf, Düsseldorf, Germany

*signifies non-member of ASH